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Conclusions: The results of this study suggest that increasing spinal 
instability, as defined by the SINS score, is associated with 
radiotherapy failure. Therefore, patients with (potentially) unstable 
painful spinal metastases should be considered for surgical 
stabilization first. 
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Purpose/Objective: Numerous treatment options are availables for 
recurrent high-grade gliomas (rHGG), including reirradiation. Both 
fractionated stereotactic radiotherapy (FSRT) and radiosurgery (SRS) 
represent an optimal method to deliver high-dose radiotherapy to the 
small volume. Reirradiation is often limited due to the dose-
prescription and target volume. The aim of this retrospective study 
was to evaluate the radiological and clinical efficacy of stereotactic 
radiotherapy for recurrent high-grade gliomas in terms of overall 
survival, radiological response and toxicity. 
Materials and Methods: Between 2004 and 2011, 128 patients (158 
lesions) with recurrent high-grade gliomas (63% Glioblastoma, WHO 
grade IV; 37% WHO grade III) were treated with CyberKnife 
stereotactic reirradiation. FSRT was performed in 96 lesions with 3-5 
fractions; SRS in 62 lesions. The median time from first irradiation and 
SRS reirradiation was 12 months (range 6-157 months). 
Results: Median survival time from the date of diagnosis was 32.1 
months (95% CI, range 25.2 to 42.9 months). Median survival time 
from the reirradiation treatment was 11,5 months (95% CI, range 10-
12 months). At 12 months, nineteen patients (15%) showed a 
radiological response (8% complete response) and at 6 and 12 months 
20 patients (16%) and 10 (8%) respectively showed a stable disease. 
There have been 19 patients (15%) of G1-G2 acute toxicity (with 
headhache, nausea, fatigue and alopecia) and 7 pts (6%) of G3-G4 late 
toxicity (radiation-induced necrosis and neurological deterioration). 
Conclusions: Salvage reirradiation with stereotactic radiotherapy for 
recurrent high-grade gliomas is safe and well tolerated. Radiographic 
response and duration of disease control suggest that this strategy is 
an effective treatment for recurrent HGG.  
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Purpose/Objective: Elderly patients with cancer represent a different 
population compared to younger patients. Comorbidity and declining 
performance may result in lesser outcome after palliative treatments. 
Our goal was to study the effect of age on response to radiotherapy 
and quality of life in patients with painful bone metastases. 
Materials and Methods: A large randomized radiotherapy trial showed 
equal effectiveness in pain relief of 8 Gy in a single fraction compared 
to 24 Gy in six fractions in patients with painful bone metastases. 
Between March 1996 and Sept 1998 1157 patients were included. At 
baseline and regular follow-up, patients completed questionnaires 
involving, among others, pain on an 11-point scale, several aspects of 
quality of life (QoL) (psychological distress, physical symptom distress, 
activity level impairment) and a verbally rated validation of QoL, all 
items derived from the Rotterdam Symptom Checklist. A visual analo-
gue score (VAS) of QoL was added. Response was calculated conform 
international standards. Patients were grouped into three age-
cohorts: A: 32-64 (n=520), B: 65-74 (n=410) and C: ≥ 75 years (n=227). 
For categorical variables, χ-square was used, for continuous variables, 
one-way ANOVA, with Bonferroni post-hoctesting. For survival and 
response analyses, the Kaplan Meier method and Cox-regression were 
used. 
Results: At baseline, visually and verbally rated QoL and QoL-
sumscores were available in 92%, 94% and 94% respectively. Elderly 
patients had worse performance at inclusion (Karnofsky Performance 
Score 20-60: 26%(A), 29%(B), 39%(C), p=0.004). When assessing base-
line QoL in different age groups, a difference in activity level was 
noticed (p<0.001, table 1), with significantly more impairment in 
group C compared to group B (p=0.01), and to A (p<0.001). Other QoL 
items were similar among age groups (table 1). During follow up, the 
decline in QoL was similar between the three age groups. Median 
survival was 35, 27 and 27 weeks for increasing age groups (p=0.05). 
Although elderly patients tended to respond less to radiation therapy 
compared to younger patients, there was still a significant response: C 
(67%) compared to A (78%, p=0.07), and to B (74%, p=0.36). No differ-
ences in mean time to response or between treatment arms were 
seen. In multivariate analysis, only primary tumor and performance 
score were significantly associated with response.  
 
 
Conclusions: Although at baseline elderly patients had a higher 
activity level impairment, and a worse performance score when 
compared to younger patients, they did not evaluate their overall QoL 
as inferior. Moreover, the majority of elderly patients showed a 
meaningful response to radiotherapy for painful bone metastases. 
Therefore, palliative radiotherapy should be considered in elderly 
patients.  
 
 SYMPOSIUM: RECURRENT GLIOMA/GBM  
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In recent years we have made remarkable progress in molecularly 
characterizing glioma uncovering their patho-genetic evolution and 
classifying them into different subtypes. Some of these molecular 
markers have been recognized to improve diagnostic precision and 
have a prognostic or even a predictive value for patient management 
based on retrospective analysis of clinical trials. Among these markers 
are mutations in the isocitrate dehydrogenase (IDH) 1 or 2 gene that 
